Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2012

View Archived Issues

Buprenorphine/naltrexone combination evaluated in experimental cocaine dependence

Scientists identify new predictors of severe obesity

Nanofiber/VEGF therapy shows potential for use after myocardial infarction

New cause identified of severe X-linked retinitis pigmentosa

CHDI Foundation presents novel HDAC4 inhibitors

Eisai divulges new PGE2/EP4 receptor signaling suppressors

Research at Zafgen yields new candidate obesity drugs

Lykera Biomed reports novel S100-P-directed antibodies

New potential ocular medications designed in Korea

Novel candidate cancer gene therapies developed in U.S.

U.S. university receives grant to set up translational research center

Enrollment complete in two Reolysin studies

Nectid repurposes agomelatine for pain and autism

FDA approves sNDA for Tradjenta

SBIR grant supports CMV antibody program

NIAID supports tuberculosis drug discovery software development

NICE publishes draft guidance on denosumab

Lenvatinib obtains orphan drug status

AbGenomics gains FDA clearance for trial of candidate drug for autoimmune disease

New formulation of palivizumab approved in Japan

FDA clears phase I trial of H5N1 vaccine with GLA vaccine adjuvant

Japanese approval for new dosage of Amaryl

New indication approved for Neoral and Sandimmun in Japan

New phase I study of F-351 begins in China

U.K. alliance set to launch AZD-8931 combination trial

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...